Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Venlafaxine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193
View directory record Official record
Conditions
Healthy Subjects
Interventions
Venlafaxine, Moxifloxacin, Drug - placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 4, 2026, 4:03 PM EDT
Suspended Phase 3 Interventional

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer

NCT04973930
View directory record Official record
Conditions
Major Depressive Disorder, Breast Cancer, Venlafaxine
Interventions
Interpersonal Psychotherapy, Venlafaxine HCl ER
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program

NCT00401726
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Venlafaxine ER, Dialogues Time to Talk Program
Drug · Behavioral
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
44
States / cities
Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Sep 4, 2026, 4:03 PM EDT
Terminated Phase 1 Interventional

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

NCT03274817
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Escitalopram Pill, Venlafaxine Pill, Placebo Oral Tablet
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression

NCT00001483
View directory record Official record
Conditions
Bipolar Disorder, Depressive Disorder
Interventions
buproprion (Wellbutrin), sertraline (Zoloft), venlafaxine (Effexor)
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea

NCT02714400
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Venlafaxine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

NCT01235338
View directory record Official record
Conditions
Healthy
Interventions
LDX + Venlafaxine XR, Venlafaxine XR + LDX
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)

NCT00892047
View directory record Official record
Conditions
Depression
Interventions
venlafaxine XR plus aripiprazole, venlafaxine plus placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 3 Interventional

Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women

NCT00030914
View directory record Official record
Conditions
Hot Flashes
Interventions
medroxyprogesterone, venlafaxine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

NCT03574792
View directory record Official record
Conditions
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Venlafaxine and Hypnosis or Focused Attention in Treating Patients with Hot Flashes

NCT01000623
View directory record Official record
Conditions
Hot Flashes
Interventions
venlafaxine, placebo, hypnotherapy, mind-body intervention procedure
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels

NCT01867255
View directory record Official record
Conditions
Bariatric Surgery, Gastric Bypass, Roux-en-Y Gastric Bypass
Interventions
venlafaxine ER (extended-release) 75 mg
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Psychosocial and Medication Treatment for Anxiety in Alcoholism

NCT00248612
View directory record Official record
Conditions
Alcohol-Related Disorders, Anxiety Disorders
Interventions
Venlafaxine, CBT, Progressive muscle relaxation therapy (PMR), Placebo medication
Drug · Behavioral · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

NCT01418209
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Disturbance
Interventions
Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Chestnut Hill, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR

NCT00183274
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Venlafaxine XR, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise

NCT02407704
View directory record Official record
Conditions
Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression, Major Depressive Disorder
Interventions
Venlafaxine XR, Aerobic Exercise, Lorazepam
Drug · Other
Lead sponsor
Kirk Erickson, PhD
Other
Eligibility
60 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

ADAPT: Addressing Depression and Pain Together

NCT01124188
View directory record Official record
Conditions
Depression, Back Pain
Interventions
Higher-dose venlafaxine, Supportive management, Problem Solving Therapy for Depression and Pain
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Venlafaxine for Hot Flashes After Breast Cancer

NCT00198250
View directory record Official record
Conditions
Breast Cancer
Interventions
venlafaxine
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2008 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers

NCT01350921
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Ticagrelor, Venlaflaxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 4, 2026, 4:03 PM EDT
Completed No phase listed Observational

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
View directory record Official record
Conditions
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 4, 2026, 4:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders

NCT00001478
View directory record Official record
Conditions
Healthy, Mood Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 4 Interventional

Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl

NCT00788944
View directory record Official record
Conditions
Depression
Interventions
blood draw
Procedure
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
52
States / cities
Birmingham, Alabama • Tuscon, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Project to Improve Symptoms and Mood in People With Spinal Cord Injury

NCT00592384
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Spinal Cord Injuries
Interventions
venlafaxine XR, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Sep 4, 2026, 4:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 4, 2026, 4:03 PM EDT